ABVC BioPharma, Inc. (NASDAQ: ABVC) announced the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, highlighting a transformative year with substantial balance sheet growth and strategic long-term asset positioning. Total assets surged to $21,062,203, a 179% increase from $7,539,907 in 2024. Net property and equipment rose to $12,835,409 from $511,088, primarily due to the strategic acquisition of land and development-oriented assets in Asia.
Management believes the 2025 fiscal year represents a structural strengthening of the company’s balance sheet and asset foundation. The company reported total assets of $21.06 million, property and equipment (net) of $12.84 million, operating lease right-of-use assets of $1.91 million, and long-term investments of $1.88 million as of December 31, 2025.
Over prior years, ABVC strategically licensed its core drug programs to a subsidiary and related parties: its CNS pipeline to AiBtl BioPharma, oncology programs to OncoX BioPharma, and ophthalmology programs to ForSeeCon Eye Corporation. Under this structure, the subsidiary and related parties handle clinical development, reducing ABVC’s direct clinical cash burn exposure while retaining licensing economics and equity participation. This model enables ABVC to separate development risk from long-term value participation.
In parallel, ABVC is strengthening its long-term infrastructure positioning in Asia through direct and subsidiary strategic land asset acquisitions. In Longtan District, Taoyuan, the company holds 5,995.41 square meters valued at $4.6 million as of December 31, 2025. The land is a strategic reserve asset with flexible future use potential, including healthcare-related applications or supportive infrastructure. In Puli Township, Nantou, ABVC acquired 69,230.90 square meters independently appraised at approximately $8.0 million as of January 30, 2026. The Puli development plan focuses on establishing a medicinal plant cultivation base, supporting pharmaceutical supply chain localization, and creating an agricultural-biotech integration platform, with projected annual output value estimated between $60,000 to $360,000 depending on processing depth.
The potential increase in fixed and real assets reflects ABVC’s strategic evolution from a purely IP-driven biotech structure toward a hybrid model combining intellectual property, licensing revenue potential, equity participation in development subsidiaries, and tangible long-term physical assets.
ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. The company utilizes in-licensed technology from its network of research institutions including Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the company intends to conduct pivotal clinical trials (Phase III) through global partnerships.
This press release contains forward-looking statements. Such statements may be preceded by words like “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. Forward-looking statements are not guarantees of future performance and are subject to various known and unknown risks and uncertainties. More detailed information is set forth in the company’s filings with the Securities and Exchange Commission (SEC), including the Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, available at http://www.sec.gov.
